Netupitant and Palonosetron Hydrochloride and Turalio
Determining the interaction of Netupitant and Palonosetron Hydrochloride and Turalio and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of pexidartinib with moderate CYP450 3A4 inhibitors may increase the plasma concentrations and the risk of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of pexidartinib. Concomitant administration of itraconazole, a strong CYP450 3A4 inhibitor, increased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 48% and 70%, respectively. No data are available regarding the effects that other, less potent CYP450 3A4 inhibitors may have on the pharmacokinetics of pexidartinib. MANAGEMENT: Caution is advised if pexidartinib is used with moderate CYP450 3A4 inhibitors. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:MONITOR: Coadministration of pexidartinib with moderate CYP450 3A4 inhibitors may increase the plasma concentrations and the risk of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of pexidartinib. Concomitant administration of itraconazole, a strong CYP450 3A4 inhibitor, increased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 48% and 70%, respectively. No data are available regarding the effects that other, less potent CYP450 3A4 inhibitors may have on the pharmacokinetics of pexidartinib.
MANAGEMENT: Caution is advised if pexidartinib is used with moderate CYP450 3A4 inhibitors. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: netupitant / palonosetron
Brand name: Akynzeo
Synonyms: Netupitant and palonosetron, Netupitant and Palonosetron
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Netupitant and Palonosetron Hydrochloride-Turmeric
- Netupitant and Palonosetron Hydrochloride-Tusicof
- Netupitant and Palonosetron Hydrochloride-Tusnel
- Netupitant and Palonosetron Hydrochloride-Tusnel C
- Netupitant and Palonosetron Hydrochloride-Tusnel Pediatric Drops
- Netupitant and Palonosetron Hydrochloride-Tusnel-DM Pediatric Drops
- Turalio-Neuac
- Turalio-Neuac Gel
- Turalio-Neuac Kit
- Turalio-Neulasta
- Turalio-Neulasta Delivery Kit
- Turalio-Neulasta Onpro Kit